Suppr超能文献

用于DNA甲基化分析的循环游离肿瘤DNA的酶促转化和亚硫酸氢盐转化的比较。

Comparison of enzymatic and bisulfite conversion of circulating cell-free tumor DNA for DNA methylation analyses.

作者信息

Kresse Stine H, Thorkildsen Evy Marie, Brandt-Winge Sara, Pharo Heidi, Vedeld Hege Marie, Lind Guro E

机构信息

Department of Molecular Oncology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Montebello, 0379, Norway.

Department of Biosciences, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.

出版信息

Clin Epigenetics. 2025 Jun 4;17(1):93. doi: 10.1186/s13148-025-01901-4.

Abstract

BACKGROUND

Detection of DNA methylation biomarkers in circulating cell-free DNA (cfDNA) has great clinical potential for cancer management, but there is a high need for method optimization and standardization. Bisulfite conversion of DNA is the gold-standard pre-treatment method for DNA methylation analyses, but causes also DNA fragmentation and loss. Enzymatic conversion of DNA represents a promising alternative due to the more gentle treatment minimizing damage to DNA. The aim of this study was to evaluate and compare enzymatic and bisulfite conversion to identify the best pre-treatment method for detecting DNA methylation biomarkers in cfDNA from plasma using droplet digital PCR (ddPCR).

RESULTS

The performance of the NEBNext Enzymatic Methyl-seq Kit (both the full kit intended for sequencing and the sub-component NEBNext Enzymatic Methyl-seq Conversion Module) and the EpiTect Plus DNA Bisulfite Kit was evaluated and compared using normal cfDNA and tumor cfDNA samples from colorectal cancer patients. The cytosine conversion efficiency was 99-100% for both enzymatic and bisulfite conversion. Enzymatic conversion resulted in longer DNA fragments with higher peak fragment sizes compared to bisulfite conversion, but the DNA recovery was considerably lower after enzymatic conversion (34-47%) compared to bisulfite conversion (61-81%). For enzymatic conversion, the full kit gave slightly better DNA recovery than the conversion module. A comparison of five magnetic bead brands, as well as several different magnetic bead-to-sample ratios revealed no major improvements in DNA recovery for the enzymatic conversion. DNA methylation of the biomarker BCAT1 was detected at similar rates in parallel tumor cfDNA samples pre-treated with either enzymatic or bisulfite conversion. However, enzymatic conversion resulted in lower number of positive droplets for both target and control ddPCR assays, in line with the lower DNA recovery after conversion.

CONCLUSIONS

Based on a thorough evaluation of enzymatic and bisulfite conversion of cfDNA using ddPCR, bisulfite conversion emerges as the best pre-treatment method due to higher DNA recovery after conversion and higher number of positive droplets in the ddPCR reactions.

摘要

背景

在循环游离DNA(cfDNA)中检测DNA甲基化生物标志物在癌症管理方面具有巨大的临床潜力,但对方法优化和标准化有很高需求。DNA的亚硫酸氢盐转化是DNA甲基化分析的金标准预处理方法,但也会导致DNA片段化和损失。由于处理较为温和,能最大程度减少对DNA的损伤,DNA的酶促转化是一种有前景的替代方法。本研究的目的是评估和比较酶促转化和亚硫酸氢盐转化,以确定使用液滴数字PCR(ddPCR)检测血浆cfDNA中DNA甲基化生物标志物的最佳预处理方法。

结果

使用来自结直肠癌患者的正常cfDNA和肿瘤cfDNA样本,对NEBNext酶促甲基化测序试剂盒(包括用于测序的完整试剂盒和子组件NEBNext酶促甲基化测序转化模块)和EpiTect Plus DNA亚硫酸氢盐试剂盒的性能进行了评估和比较。酶促转化和亚硫酸氢盐转化的胞嘧啶转化效率均为99 - 100%。与亚硫酸氢盐转化相比,酶促转化产生的DNA片段更长,片段大小峰值更高,但酶促转化后的DNA回收率(34 - 47%)明显低于亚硫酸氢盐转化(61 - 81%)。对于酶促转化,完整试剂盒的DNA回收率略高于转化模块。对五个磁珠品牌以及几种不同的磁珠与样本比例进行比较,结果显示酶促转化的DNA回收率没有显著提高。在用酶促转化或亚硫酸氢盐转化预处理的平行肿瘤cfDNA样本中,生物标志物BCAT1的DNA甲基化检测率相似。然而,酶促转化导致目标和对照ddPCR检测的阳性液滴数量均较低,这与转化后较低的DNA回收率一致。

结论

基于使用ddPCR对cfDNA的酶促转化和亚硫酸氢盐转化进行的全面评估,亚硫酸氢盐转化由于转化后更高的DNA回收率和ddPCR反应中更多的阳性液滴,成为最佳预处理方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a353/12135323/aa50a6a2e0e3/13148_2025_1901_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验